--- title: "Reviva Pharmaceuticals Holdings (RVPH) news: reverse split" url: "https://aibio.space/companies/reviva-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "RVPH reverse split and offering news: Reviva asks stockholders to approve reverse split of up to 1-for-100. Reviva Pharmaceuticals Holdings, Inc." --- RVPH Reviva Pharmaceuticals Holdings, Inc. OTC · United States # Reviva Pharmaceuticals Holdings (RVPH) news RVPH reverse split and offering news Listings · 2026-10-29 ## [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) The proposal goes to a virtual annual meeting on December 18, 2026. The board would pick the ratio and could decide not to split at all. ## Latest Reviva Pharmaceuticals Holdings news 1. 2025-05-30 Financings [Reviva Pharmaceuticals sets up $50 million at-the-market stock program](https://aibio.space/news/reviva-pharmaceuticals-sets-up-50-million-market-stock-program/) B. Riley Securities and Alliance Global Partners will act as sales agents for a 3% commission. The stock's last reported sale price was $1.10 on May 27, 2025. 2. 2025-03-31 Distress [Reviva Pharmaceuticals delays 2024 annual report and expects to report material weaknesses](https://aibio.space/news/reviva-pharmaceuticals-delays-2024-annual-report-expects-report/) The company said it needs more time to finalize its financial statements and audit. It plans to file within the fifteen-day extension. ## Reviva Pharmaceuticals Holdings at a glance - **Ticker**: RVPH - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $19.9 million ### Related companies - [AN2 Therapeutics](https://aibio.space/companies/an2-therapeutics/) NASDAQ: ANTX - [AbbVie](https://aibio.space/companies/abbvie/) NYSE: ABBV - [Corcept Therapeutics](https://aibio.space/companies/corcept-therapeutics/) NASDAQ: CORT - [Niki BioSolutions](https://aibio.space/companies/niki-biosolutions/) NASDAQ: NIKI - [Petros Pharmaceuticals](https://aibio.space/companies/petros-pharmaceuticals/) OTC: PTPI - [Achieve Life Sciences](https://aibio.space/companies/achieve-life-sciences/) NASDAQ: ACHV - [Collegium Pharmaceutical](https://aibio.space/companies/collegium-pharmaceutical/) NASDAQ: COLL - [Cingulate](https://aibio.space/companies/cingulate/) NASDAQ: CING ### Also on OTC - [RetinalGenix Technologies](https://aibio.space/companies/retinalgenix-technologies/) RTGN - [RepliCel Life Sciences](https://aibio.space/companies/replicel-life-sciences/) REPCF - [Northwest Biotherapeutics](https://aibio.space/companies/northwest-biotherapeutics/) NWBO - [ThermoGenesis Holdings](https://aibio.space/companies/thermogenesis/) THMO - [OSR Health](https://aibio.space/companies/osr-health/) OSRH - [LianBio](https://aibio.space/companies/lianbio/) LIANY ## What Reviva Pharmaceuticals Holdings does Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases with significant unmet medical needs. Its pipeline focuses on central nervous system, inflammatory and cardiometabolic diseases, and it uses a chemical genomics driven technology platform and proprietary chemistry. The company has two drug candidates, brilaroxazine (RP5063) and RP1208, both new chemical entities discovered in-house. Its lead candidate, brilaroxazine, is in clinical development for schizophrenia, bipolar disorder, major depressive disorder, ADHD, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. The company says brilaroxazine is also ready for clinical development for pulmonary arterial hypertension and idiopathic pulmonary fibrosis, and is in preclinical development for psoriasis. Its primary focus is completing clinical development of brilaroxazine for acute and maintenance schizophrenia. Recent developments include a one-for-twenty reverse stock split effective March 9, 2026, and a March 2026 public offering with net proceeds of approximately $8.9 million. | Product or program | What it is | Stage | |---|---|---| | Brilaroxazine (RP5063) | Multimodal serotonin, dopamine and nicotinic receptor modulator for neuropsychiatric indications | in clinical development | | RP1208 | New chemical entity discovered in-house with composition of matter patents | | Summarised from the company's [10-K filed Mar 30, 2026](https://www.sec.gov/Archives/edgar/data/1742927/000143774926010126/rvph20251231_10k.htm). ## Reviva Pharmaceuticals Holdings annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$11.7 million](https://www.sec.gov/Archives/edgar/data/1742927/000143774926010126/) | [$22.9 million](https://www.sec.gov/Archives/edgar/data/1742927/000143774926010126/) | | Net income (loss) | [-$19.9 million](https://www.sec.gov/Archives/edgar/data/1742927/000143774926010126/) | [-$29.9 million](https://www.sec.gov/Archives/edgar/data/1742927/000143774926010126/) | | Cash from operations | [-$24.6 million](https://www.sec.gov/Archives/edgar/data/1742927/000143774926010126/) | [-$33.5 million](https://www.sec.gov/Archives/edgar/data/1742927/000143774926010126/) | | Cash and equivalents | [$14.4 million](https://www.sec.gov/Archives/edgar/data/1742927/000143774926027358/) | [$13.5 million](https://www.sec.gov/Archives/edgar/data/1742927/000143774926010126/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $19.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Reviva Pharmaceuticals Holdings Did Reviva Pharmaceuticals Holdings do a reverse stock split? Our latest story on this, dated Oct 29, 2026: "Reviva asks stockholders to approve reverse split of up to 1-for-100". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/). Has Reviva Pharmaceuticals Holdings raised money recently? Our latest story on this, dated May 30, 2025: "Reviva Pharmaceuticals sets up $50 million at-the-market stock program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/reviva-pharmaceuticals-sets-up-50-million-market-stock-program/). What is the ticker symbol of Reviva Pharmaceuticals Holdings? Reviva Pharmaceuticals Holdings, Inc. trades under the ticker RVPH on OTC. Where is Reviva Pharmaceuticals Holdings listed? Reviva Pharmaceuticals Holdings, Inc. is listed on OTC. What is the SEC CIK of Reviva Pharmaceuticals Holdings? The SEC Central Index Key (CIK) for Reviva Pharmaceuticals Holdings, Inc. is 1742927. Its filings are on SEC EDGAR. How many shares does Reviva Pharmaceuticals Holdings have outstanding? 13,110,377 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Reviva Pharmaceuticals Holdings listed under? Our directory records Reviva Pharmaceuticals Holdings, Inc. under United States. What does Reviva Pharmaceuticals Holdings do? Our directory classifies Reviva Pharmaceuticals Holdings, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Reviva Pharmaceuticals Holdings? The ISIN recorded for Reviva Pharmaceuticals Holdings, Inc. is US76152G2093. Does aibio.space cover Reviva Pharmaceuticals Holdings? aibio.space lists Reviva Pharmaceuticals Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Reviva Pharmaceuticals Holdings incorporated? SEC records list its state or country of incorporation as DE. What does Reviva Pharmaceuticals Holdings develop? Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases with significant unmet medical needs. Its pipeline focuses on central nervous system, inflammatory and cardiometabolic diseases, and it uses a chemical genomics driven technology platform and proprietary chemistry. What is Brilaroxazine (RP5063) from Reviva Pharmaceuticals Holdings? Brilaroxazine (RP5063): Multimodal serotonin, dopamine and nicotinic receptor modulator for neuropsychiatric indications Stage: in clinical development. What is RP1208 from Reviva Pharmaceuticals Holdings? RP1208: New chemical entity discovered in-house with composition of matter patents Stage: not stated. Is Reviva Pharmaceuticals Holdings profitable? Reviva Pharmaceuticals Holdings, Inc. reported a net loss of $19.9 million for the fiscal year ended Dec 31, 2025, and used $24.6 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Reviva Pharmaceuticals Holdings Members talk about Reviva Pharmaceuticals Holdings (RVPH). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Reviva Pharmaceuticals Holdings, newest first. Each line links the filing it comes from. 1. 2026-10-29 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1742927/000143774926033948/rvph20261021c_pre14a.htm) 2. 2026-07-10 Listings Filed to remove its shares from exchange listing. SEC Form 25-NSE. [Source](https://www.sec.gov/Archives/edgar/data/1742927/000135445726000658/xslF25X02/primary_doc.xml) 3. 2026-05-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1742927/000143774926016538/rvph20260512_8k.htm) 4. 2026-03-05 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1742927/000143774926006991/0001437749-26-006991-index-headers.html) 5. 2026-01-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1742927/000143774926001913/rvph20260122_8k.htm) 6. 2025-12-23 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1742927/000143774925038602/rvph20251216_8k.htm) 7. 2025-11-04 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1742927/000143774925033023/rvph20251029_def14a.htm) 8. 2025-10-24 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1742927/000143774925031730/rvph20251008_pre14a.htm) 9. 2025-10-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1742927/000143774925031278/rvph20251014_8k.htm) 10. 2025-06-06 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1742927/000143774925019716/rvph20250605_8k.htm) 11. 2025-05-30 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1742927/000143774925018972/rvph20250513_8k.htm) 12. 2025-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1742927/000143774925010274/rvph20250331_nt10k.htm) 13. 2024-12-16 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1742927/000143774924037646/rvph20241215_424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:RVPH on TradingView](https://www.tradingview.com/symbols/OTC-RVPH/). ## SEC filings and registration - **SEC name**: Reviva Pharmaceuticals Holdings, Inc. - **CIK**: 1742927 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: RVPH (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 10080 N WOLFE ROAD, CUPERTINO, CA, 95014 - **Phone**: 4085018881 - **Shares outstanding**: 13,110,377 as of 2026-08-13 (10-Q filed 2026-08-12) - **Former names**: Tenzing Acquisition Corp. ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1742927/000143774926027358/rvph20260630_10q.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1742927/000143774926027356/rvph20260729_8k.htm) filed 2026-08-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1742927/000143774926016762/rvph20260331_10q.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1742927/000143774926016760/rvph20260513_8k.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1742927/000143774926016538/rvph20260512_8k.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1742927/000143774926012303/rvph20260414_8k.htm) filed 2026-04-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1742927/000143774926010140/rvph20260313_8k.htm) filed 2026-03-30 - [10-K](https://www.sec.gov/Archives/edgar/data/1742927/000143774926010126/rvph20251231_10k.htm) filed 2026-03-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001742927), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Reviva Pharmaceuticals Holdings, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker RVPH, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Reviva Pharmaceuticals Holdings, Inc. - **Ticker**: RVPH - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US76152G2093 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-RVPH/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/reviva-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Reviva Pharmaceuticals Holdings (RVPH) news: reverse split", 2026-10-31, https://aibio.space/companies/reviva-pharmaceuticals/